Purpose of review Childhood asthma is a heterogeneous disease and many children have uncontrolled disease. Therefore an individualized approach is needed to improve asthma outcomes in children. Precision medicine using clinical characteristics, biomarkers, and the rapidly involving field of genomics and pharmacogenomics aims to achieve asthma control and reduce future risks with less side-effects in individual children with asthma. Recent findings It is not yet possible to select treatment options on clinical characteristics. Novel monoclonal antibodies are efficacious in patients with severe, eosinophilic asthma. Reduced lung function growth and early decline is a prevalent finding in children with persistent asthma. Pharmacogenetic studies have identified children at risk for cortisol suppression when using inhaled corticosteroids. Summary Clinical characteristics and simple biomarkers like eosinophils, IgE, and the fraction of exhaled nitric oxide may be used in clinical practice for a basic precision medicine approach, deciding which children will have the best chance to respond to inhaled corticosteroids and to the biologicals omalizumab and mepolizumab. Further application of pharmacogenomics and breathomics needs additional studies before they can be applied as tools for precision medicine in individual children with asthma.

Additional Metadata
Keywords biologicals, biomarkers, childhood asthma, pharmacogenomics, precision medicine
Persistent URL dx.doi.org/10.1097/aci.0000000000000517, hdl.handle.net/1765/117070
Series VSNU Open Access deal
Journal Current Opinion in Allergy and Clinical Immunology
Citation
Slob, E.M., Maitland-van der Zee, A-H, Koppelman, G.H, & Pijnenburg, M.W.H. (2019). Precision medicine in childhood asthma. Current Opinion in Allergy and Clinical Immunology, 19(2), 141–147. doi:10.1097/aci.0000000000000517